GRI · GRI Bio, Inc.
$1.48
-0.03 (-1.99%)
At close · Jul 22
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Therefore, there is substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these financial statements.”View the 10-Q filed May 13, 2026
Market Cap
$2.62M
Shares
1.77M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2021
Net Income
-$11.96M
-45.7%
FY2025
Operating Margin
-4788%
FY2020
Diluted EPS
-$121.80
+92.1%
FY2025
Operating Cash Flow
-$10.19M
-18.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $0 | — | — | — | — | $0 | $100K | |
| $5.54M | $6.82M | $3.77M | $3.23M | $242K | $5.19M | $3.71M | |
| $5.39M | $5.16M | $4.47M | $8.16M | $2M | $4.07M | $1.18M | |
| $10.93M | $11.98M | $8.24M | $11.39M | $2.24M | $9.26M | $4.89M | |
| -$10.93M | -$11.98M | -$8.24M | -$11.39M | -$2.24M | -$9.26M | -$4.79M | |
| — | — | — | — | — | — | -4788% | |
| — | — | $0 | $250K | $0 | $61K | $0 | |
| — | $3000 | $2000 | — | — | — | — | |
| -$10.91M | -$11.96M | -$8.21M | -$13.04M | -$3.22M | -$9.3M | -$4.82M | |
| — | — | — | — | — | — | -4822% | |
| — | -$11.96M | -$10.12M | -$13.04M | — | — | — | |
| -$6.78M | — | — | — | -$7.02M | -$9.31M | -$4.82M | |
| USD/shares | — | -$121.80 | -$1,545.55 | -$140,506.52 | -$154,390.60 | -$1,845,261.60 | -$1,390,443.60 |
| USD/shares | — | -$121.80 | -$1,545.55 | -$140,506.52 | -$154,390.60 | -$1,845,261.60 | -$1,390,443.60 |
| shares | — | 98.16K | 6547 | 92.7857 | 20.8458 | 5.0336 | 3.4677 |
| shares | — | 98.16K | 6547 | 92.7857 | 20.8458 | 5.0336 | 3.4677 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.67×
P/E (TTM)
0.04×
Biotechnology median 7.06×